Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07117890
PHASE2

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.

Official title: a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

34

Start Date

2025-02-07

Completion Date

2027-05-30

Last Updated

2025-12-24

Healthy Volunteers

No

Interventions

DRUG

sunvozertinib 300mg

sunvozertinib monotherapy, 300mg QD

DRUG

sunvozertinib 200mg

sunvozertinib monotherapy, 200mg QD

Locations (1)

Fudan university shanghai cancer center

Shanghai, China